Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    21439048 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Condition: Acute Gout
Interventions: Drug: Canakinumab;   Drug: Triamcinolone acetonide

Study has passed its completion date and status has not been verified in more than two years.